CJC-1295 with DAC vs Metformin
Well Studied vs FDA Approved
synergistic Mechanism-based · 51% CJC-1295 with DAC helps counteract the insulin-disrupting effects of Metformin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
CJC-1295 with DAC Metformin
Weight 3,647.28 Da 129.16 Da
Half-life 6-8 days ~5 hours
Chain 30 amino acids —
Type GHRH analog with DAC Biguanide (C4H11N5)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
CJC-1295 with DAC Metformin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.